Seven-Year MiSight® 1 day Contact Lens Study Indicates No Myopia Control Rebound in Children
Wednesday, November 3 2021 | 16 h 38 min | News
CooperVision announced new seven-year findings from its pivotal MiSight® 1 day contact lens clinical trial. Twelve months following treatment cessation, mean axial elongation data indicate no evidence of rebound effect, meaning the myopia control gains are retained.
The study is the world’s longest continuous running soft contact lens clinical trial for myopia control. CooperVision previously reported that MiSight® 1 day showed sustained slowing of myopia progression across multiple years of treatment. This was observed in a cohort that wore MiSight® 1 day for the study’s first six years as well as the original control group who were switched into MiSight® 1 day for three years.
“Our unparalleled research clearly illustrates the tremendous potential of MiSight® 1 day for children of different ages and with different levels of myopia, regardless of when they start treatment.3 With these results, eye care professionals should be even more confident in prescribing MiSight® 1 day,” said Paul Chamberlain, BSc (Hons), MCOptom, the study’s principal investigator and CooperVision Director of Research Programs.
The latest data analysis goes even deeper to illustrate that MiSight® 1 day offers a highly desired proportional myopia control treatment effect. Abnormal axial length growth slowed by an average of approximately 50% with all tested ages (8-17). Because younger children’s myopia progresses faster than in older children, introducing MiSight® 1 day at the earliest opportunity may offer the maximum cumulative benefit over time.4
In the study’s seventh year, participants were transitioned from MiSight® 1 day to a single vision contact lens to evaluate if treatment gains would be retained. Myopic progression then occurred only at anticipated ‘age-normal’ levels—not at an accelerated “catch up” rate that would offset prior myopia control gains.1,2 This indicates no rebound effect.
“We saw these children grow into young adults during their seven years in the study. It is personally as well as professionally fulfilling to know that the benefits of treatment are retained. As MiSight® 1 day becomes more widely available and as myopia management becomes the standard of care, I hope other eye care professionals will experience that same joy,” said study investigator Nicola Logan, PhD, Professor of Optometry and Physiological Optics, Aston University.
CooperVision researchers are sharing their findings at this week’s American Academy of Optometry Annual Meeting, the globally-renowned scientific and clinical conference.
Click HERE for the full press release.
